CITATION REPORT List of articles citing

Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment

DOI: 10.1111/j.1528-1167.2005.46304.x Epilepsia, 2005, 46, 643-7.

Source: https://exaly.com/paper-pdf/38166446/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
190	Pharmacogenetics of epilepsy: one step forward?. 2005 , 5, 236-8		2
189	MDR1 genotype-related pharmacokinetics: fact or fiction?. <i>Drug Metabolism and Pharmacokinetics</i> , 2005 , 20, 391-414	2.2	117
188	RLIP76, a non-ABC transporter, and drug resistance in epilepsy. 2005 , 6, 61		64
187	Limited P-glycoprotein mediated efflux for anti-epileptic drugs. 2006 , 14, 291-300		62
186	Refractory epilepsy: mechanisms and solutions. 2006 , 6, 397-406		127
185	Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006 , 2, 651-74	5.5	42
184	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. 2006 , 234, 4-33		190
183	Single nucleotide polymorphisms in the multidrug resistance 1 gene in Korean epileptics. 2006 , 15, 67-7	'2	64
182	Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy. 2006 , 15, 344-7		67
181	Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. <i>Pharmacogenetics and Genomics</i> , 2006 , 16, 439-50	1.9	58
180	Bibliography. Current world literature. Developmental disorders. 2006 , 19, 200-6		
179	Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. <i>Epilepsia</i> , 2006 , 47, 449; author reply 450	6.4	6
178	Response: Lack of Association between the C3435T Polymorphism in the Human Multidrug Resistance (MDR1) Gene and Response to Antiepileptic Drug Treatment. <i>Epilepsia</i> , 2006 , 47, 450-450	6.4	
177	Central and peripheral benzodiazepine receptors. <i>Epilepsia</i> , 2006 , 47, 450-1	6.4	1
176	Epileptogenesis due to peripheral injury as a cause of focal epilepsy. <i>Epilepsia</i> , 2006 , 47, 451; author reply 451-2	6.4	1
175	Response: Epileptogenesis due to Peripheral Injury as a Cause of Focal Epilepsy. <i>Epilepsia</i> , 2006 , 47, 451	-6.542	3
174	Insulinoma presenting as refractory late-onset epilepsy. <i>Epilepsia</i> , 2006 , 47, 452; author reply 452	6.4	4

(2007-2006)

173	Response: Insulinoma Presenting as Refractory Late-onset Epilepsy. <i>Epilepsia</i> , 2006 , 47, 452-452	6.4	
172	Introduction and Overview. <i>Epilepsia</i> , 2006 , 47, 1-2	6.4	1
171	Epileptogenesis and rational therapeutic strategies. 2006 , 113, 139-55		39
170	Pharmacogenetics and the concept of individualized medicine. 2006 , 6, 16-21		155
169	Defining the clinical role of pharmacogenetics in antiepileptic drug therapy. 2006 , 6, 357-9		8
168	Polymorphic variants of the multidrug resistance gene Mdr1a and response to antiepileptic drug treatment in the kindling model of epilepsy. 2006 , 550, 54-61		6
167	The potential of pharmacogenetics in the treatment of epilepsy. 2006 , 10, 57-65		41
166	In vitro responsiveness of human-drug-resistant tissue to antiepileptic drugs: insights into the mechanisms of pharmacoresistance. <i>Brain Research</i> , 2006 , 1086, 201-13	3.7	20
165	MDR1 gene polymorphisms and clinical relevance. 2006 , 33, 93-104		31
164	Update on pharmacogenetics in epilepsy: a brief review. 2006 , 5, 189-96		59
163	Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study. 2006 , 5, 668-76		63
162	Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. 2006 , 112, 457-73		274
161	MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. 2006 , 95, 2293-308		113
160	Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences. 2006 , 1, 291-309		16
159	Genetic association studies in epilepsy pharmacogenomics: lessons learnt and potential applications. <i>Pharmacogenomics</i> , 2006 , 7, 731-45	2.6	20
158	ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. <i>Pharmacogenomics</i> , 2006 , 7, 551-61	2.6	137
157	Challenges and opportunities in the application of pharmacogenetics to antiepileptic drug therapy. <i>Pharmacogenomics</i> , 2006 , 7, 89-103	2.6	14
156	Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. <i>Pharmacogenomics</i> , 2007 , 8, 29-39	2.6	78

155	The association between polymorphisms in RLIP76 and drug response in epilepsy. <i>Pharmacogenomics</i> , 2007 , 8, 1715-22	2.6	15
154	Multidrug Resistance Protein: P-Glycoprotein. 223-262		13
153	Common ABCB1 polymorphisms are not associated with multidrug resistance in epilepsy using a gene-wide tagging approach. <i>Pharmacogenetics and Genomics</i> , 2007 , 17, 217-20	1.9	39
152	Clinical implications of mechanisms of resistance to antiepileptic drugs. 2007 , 13, S38-46		8
151	Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. <i>Epilepsy and Behavior</i> , 2007 , 11, 112-7	3.2	79
150	Polymorphisms of Drug Transporters and Clinical Relevance. 619-663		
149	Multidrug resistance in epilepsy: a pharmacogenomic update. 2007 , 8, 1441-9		38
148	Various pharmacogenetic aspects of antiepileptic drug therapy: a review. 2007 , 21, 143-64		29
147	Epilepsy: Mechanisms of Drug Action and Clinical Treatment. 2007,		
146	ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. 2007 , 7, 154-79		220
145	The Promise of Individualized Therapy. 1463-1489		
144	Enaminones: Exploring additional therapeutic activities. 2007 , 96, 2509-31		70
143	The controversial association of ABCB1 polymorphisms in refractory epilepsy: an analysis of		59
	multiple SNPs in an Irish population. <i>Epilepsy Research</i> , 2007 , 73, 192-8	3	<i>J</i>
142		3	114
142 141	multiple SNPs in an Irish population. <i>Epilepsy Research</i> , 2007 , 73, 192-8	6.4	
	multiple SNPs in an Irish population. <i>Epilepsy Research</i> , 2007 , 73, 192-8 ABCB1 pharmacogenetics: progress, pitfalls, and promise. 2007 , 81, 265-9 Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate		114
141	multiple SNPs in an Irish population. <i>Epilepsy Research</i> , 2007 , 73, 192-8 ABCB1 pharmacogenetics: progress, pitfalls, and promise. 2007 , 81, 265-9 Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil. <i>Epilepsia</i> , 2007 , 48, 1774-1784	6.4	114

(2008-2007)

137	Assessment of hairline EEG as a screening tool for nonconvulsive status epilepticus. <i>Epilepsia</i> , 2007 , 48, 2374-5; author reply 2375	6.4	3
136	Assessment of hairline EEG as a screening tool for nonconvulsive status epilepticus: Response to Bubrick et al <i>Epilepsia</i> , 2007 , 48, 2375-2375	6.4	
135	Next Month in Epilepsia. <i>Epilepsia</i> , 2007 , 48, 2376-2376	6.4	
134	Online Early. <i>Epilepsia</i> , 2007 , 48, 2376-2376	6.4	
133	Announcements. <i>Epilepsia</i> , 2007 , 48, 2376-2377	6.4	
132	Calendar of Meetings. <i>Epilepsia</i> , 2007 , 48, 2378-2378	6.4	
131	Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. 2007 , 41, 179-88		75
130	Potential impact of ABCB1 (p-glycoprotein) polymorphisms on avermectin toxicity in humans. 2007 , 81, 553-63		39
129	Multidrug resistance in patients undergoing resective epilepsy surgery is not associated with C3435T polymorphism in the ABCB1 (MDR1) gene. <i>Epilepsy Research</i> , 2008 , 80, 42-6	3	24
128	Association of ABCB1 genetic variants 3435C>T and 2677G>T to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients. <i>Epilepsia</i> , 2008 , 49, 1555-61	6.4	33
127	Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. 2008 , 42, 89-97		65
126	Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. 2008 , 42, 884-93		37
125	Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. 2008 , 38, 802-32		424
124	Pharmacogenomics and Personalized Medicine. <i>Methods in Pharmacology and Toxicology</i> , 2008 ,	1.1	2
123	Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima. 2008 , 383, 281-91		195
122	[Drug resistance in partial epilepsy: epidemiology, mechanisms, pharmacogenetics and therapeutical aspects]. 2008 , 54, 259-64		5
121	The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy. 2008 , 17, 524-30		60
120	MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. 2008 , 32, 1439-44		53

119	ABC multidrug transporters: structure, function and role in chemoresistance. <i>Pharmacogenomics</i> , 2008 , 9, 105-27	2.6	734
118	Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. 2008 , 60, 196-209		285
117	A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. 2008 , 18, 157-69		125
116	Association of MDR1 (C3435T) polymorphism and resistance to carbamazepine in epileptic patients from Turkey. 2008 , 59, 67-70		53
115	Pharmacogenetics in epilepsy treatment: sense or nonsense?. 2008 , 5, 123-131		5
114	One of the hottest topics in epileptology: ABC proteins. Their inhibition may be the future for patients with intractable seizures. 2008 , 30, 920-5		24
113	Bayesian survival analysis in genetic association studies. 2008 , 24, 2030-6		4
112	Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. <i>Pharmacogenetics and Genomics</i> , 2008 , 18, 390-402	1.9	44
111	. 2009,		9
110	Role of multidrug transporters in neurotherapeutics. 2009 , 12, 89-98		11
110	Role of multidrug transporters in neurotherapeutics. 2009 , 12, 89-98 The clinical impact of pharmacogenetics on the treatment of epilepsy. <i>Epilepsia</i> , 2009 , 50, 1-23	6.4	184
		6.4	
109	The clinical impact of pharmacogenetics on the treatment of epilepsy. <i>Epilepsia</i> , 2009 , 50, 1-23 Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant		184
109	The clinical impact of pharmacogenetics on the treatment of epilepsy. <i>Epilepsia</i> , 2009 , 50, 1-23 Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis. <i>Epilepsia</i> , 2009 , 50, 898-903 Multidrug-resistant genotype (ABCB1) and seizure recurrence in newly treated epilepsy: data from	6.4	184 92
109 108 107	The clinical impact of pharmacogenetics on the treatment of epilepsy. <i>Epilepsia</i> , 2009 , 50, 1-23 Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis. <i>Epilepsia</i> , 2009 , 50, 898-903 Multidrug-resistant genotype (ABCB1) and seizure recurrence in newly treated epilepsy: data from international pharmacogenetic cohorts. <i>Epilepsia</i> , 2009 , 50, 1689-96 Letter: lack of association between MDR1 polymorphisms and pharmacoresistance to	6.4	184 92 38
109 108 107	The clinical impact of pharmacogenetics on the treatment of epilepsy. <i>Epilepsia</i> , 2009 , 50, 1-23 Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis. <i>Epilepsia</i> , 2009 , 50, 898-903 Multidrug-resistant genotype (ABCB1) and seizure recurrence in newly treated epilepsy: data from international pharmacogenetic cohorts. <i>Epilepsia</i> , 2009 , 50, 1689-96 Letter: lack of association between MDR1 polymorphisms and pharmacoresistance to anticonvulsive drugs in patients with childhood-onset epilepsy. <i>Epilepsia</i> , 2009 , 50, 1835-7 Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug	6.4 6.4	184 92 38
109 108 107 106	The clinical impact of pharmacogenetics on the treatment of epilepsy. <i>Epilepsia</i> , 2009 , 50, 1-23 Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis. <i>Epilepsia</i> , 2009 , 50, 898-903 Multidrug-resistant genotype (ABCB1) and seizure recurrence in newly treated epilepsy: data from international pharmacogenetic cohorts. <i>Epilepsia</i> , 2009 , 50, 1689-96 Letter: lack of association between MDR1 polymorphisms and pharmacoresistance to anticonvulsive drugs in patients with childhood-onset epilepsy. <i>Epilepsia</i> , 2009 , 50, 1835-7 Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy. <i>Epilepsy Research</i> , 2009 , 84, 86-90	6.4 6.4 3	184 92 38 10

(2011-2009)

101	No association of ABCB1 polymorphisms with drug-refractory epilepsy in a north Indian population. <i>Epilepsy and Behavior</i> , 2009 , 14, 78-82	3.2	56
100	Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 353	-62	79
99	Genetic Polymorphisms in ABC Transporters. 411-436		
98	Predisposition to epilepsydoes the ABCB1 gene play a role?. <i>Epilepsia</i> , 2010 , 51, 1882-5	6.4	23
97	Genetic variations and response to antiepileptic drug. 2010 , 3, 65-71		
96	Multidrug resistance 1 (MDR1) gene polymorphisms in childhood drug-resistant epilepsy. 2010 , 25, 1485	5-90	24
95	Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients. 2010 , 92, 1207-12		39
94	MDR1 gene polymorphisms and response to acute risperidone treatment. 2010 , 34, 387-92		28
93	Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. 2010 , 31, 246-	54	270
92	Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. 2010 , 19, 93-101		66
91	ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: a systematic review and meta-analysis. 2010 , 19, 339-46		66
90	Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment. <i>Pharmacogenomics</i> , 2010 , 11, 927-41	2.6	38
89	Drug Transporters. Handbook of Experimental Pharmacology, 2011,	3.2	13
88	Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. <i>Epilepsy and Behavior</i> , 2011 , 21, 27-30	3.2	45
87	P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handbook of Experimental Pharmacology, 2011 , 261-83	3.2	135
86	Methodological quality in pharmacogenetic studies with binary assessment of treatment response: a review. <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 243-50	1.9	7
85	Association analysis of intractable epilepsy with C3435T and G2677T/A ABCB1 gene polymorphisms in Iranian patients. <i>Epileptic Disorders</i> , 2011 , 13, 155-65	1.9	20
84	Lack of association between ABCB1 gene polymorphisms and pharmacoresistant epilepsy: an analysis in a western Chinese pediatric population. <i>Brain Research</i> , 2011 , 1391, 114-24	3.7	29

83	Association of ABCB1 gene polymorphisms and their haplotypes with response to antiepileptic drugs: a systematic review and meta-analysis. <i>Pharmacogenomics</i> , 2011 , 12, 713-25	2.6	47
82	Potential role of multidrug resistant proteins in refractory epilepsy and antiepileptic drugs interactions. <i>Drug Metabolism and Drug Interactions</i> , 2011 , 26, 21-6		34
81	Drug resistance in epilepsy and the ABCB1 gene: The clinical perspective. <i>Indian Journal of Human Genetics</i> , 2011 , 17 Suppl 1, S12-21		6
80	Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population. <i>Indian Journal of Human Genetics</i> , 2011 , 17 Suppl 1, S32-40		47
79	Biomarkers for antiepileptic drug response. <i>Biomarkers in Medicine</i> , 2011 , 5, 635-41	2.3	15
78	Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. <i>Pharmacogenomics</i> , 2011 , 12, 1525-33	2.6	72
77	Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 518-25	3.2	32
76	The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs. <i>Pharmacological Reports</i> , 2012 , 64, 1011-9	3.9	70
75	The association of C3435T single-nucleotide polymorphism, Pgp-glycoprotein gene expression levels and carbamazepine maintenance dose in patients with epilepsy. <i>Neuropsychiatric Disease and Treatment</i> , 2012 , 8, 191-6	3.1	10
74	Cerebral expression of drug transporters in epilepsy. <i>Advanced Drug Delivery Reviews</i> , 2012 , 64, 919-29	18.5	66
73	Sequential methods for pharmacogenetic studies. <i>Computational Statistics and Data Analysis</i> , 2012 , 56, 1221-1231	1.6	O
72	The association of MDR1 C3435T and G2677T/A polymorphisms with plasma platelet-activating factor levels and coronary artery disease risk in Turkish population. <i>Gene</i> , 2013 , 527, 301-5	3.8	8
71	P-glycoprotein (MDR1/ABCB1). 2013 , 271-293		1
70	The role of mdr1 gene polymorphisms in type 2 Diabetes Mellitus. <i>Turkish Journal of Biochemistry</i> , 2013 , 38, 186-192	0.3	1
69	. 2014,		8
68	The effects of ABCC2 G1249A polymorphism on the risk of resistance to antiepileptic drugs: a meta-analysis of the literature. <i>Genetic Testing and Molecular Biomarkers</i> , 2014 , 18, 106-11	1.6	21
67	Higher frequency of C.3435 of the ABCB1 gene in patients with tramadol dependence disorder. <i>American Journal of Drug and Alcohol Abuse</i> , 2014 , 40, 317-20	3.7	12
66	The drug-transporter gene MDR1 C3435T and G2677T/A polymorphisms and the risk of multidrug-resistant epilepsy in Turkish children. <i>Molecular Biology Reports</i> , 2014 , 41, 331-6	2.8	26

65	Significance of MDR1 gene polymorphism C3435T in predicting drug response in epilepsy. <i>Epilepsy Research</i> , 2014 , 108, 251-6	3	30
64	Association between MDR1 C3435T polymorphism and refractory epilepsy in the Chinese population: a systematic review and meta-analysis. <i>Epilepsy and Behavior</i> , 2014 , 36, 173-9	3.2	12
63	The ABCB1-C3435T polymorphism likely acts as a risk factor for resistance to antiepileptic drugs. <i>Epilepsy Research</i> , 2014 , 108, 1052-67	3	16
62	Multidrug resistance 1 (MDR1) 3435C/T genotyping in childhood drug-resistant epilepsy. <i>Brain and Development</i> , 2014 , 36, 137-42	2.2	15
61	Polymorphisms of Drug Transporters and Clinical Relevance. 2014 , 389-407		1
60	Association of ABCB1 C3435T polymorphism with phenobarbital resistance in Thai patients with epilepsy. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015 , 40, 315-9	2.2	17
59	ABCB1 gene C3435T polymorphism and drug resistance in epilepsy: evidence based on 8,604 subjects. <i>Medical Science Monitor</i> , 2015 , 21, 861-8	3.2	16
58	Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders. <i>Brain Research</i> , 2015 , 1628, 298-316	3.7	132
57	Polymorphisms of ABCG2, ABCB1 and HNF4D re associated with Lamotrigine trough concentrations in epilepsy patients. <i>Drug Metabolism and Pharmacokinetics</i> , 2015 , 30, 282-7	2.2	31
56	Relationship between ABCB1 3435TT genotype and antiepileptic drugs resistance in Epilepsy: updated systematic review and meta-analysis. <i>BMC Neurology</i> , 2017 , 17, 32	3.1	50
55	Polymorphism of the multidrug resistance 1 gene MDR1 G2677T/A (rs2032582) and the risk of drug-resistant epilepsy in the Polish adult population. <i>Acta Neurologica Belgica</i> , 2017 , 117, 849-855	1.5	4
54	The effect of MDR1 C3435T polymorphism on the eradication rate of H. pylori infection in PPI-based triple therapy: A meta-analysis. <i>Medicine (United States)</i> , 2017 , 96, e6489	1.8	1
53	Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers. Frontiers in Neurology, 2017, 8, 301	4.1	184
52	The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis. <i>Epilepsia</i> , 2018 , 59, 2179-2193	6.4	149
51	Clinical reappraisal of the influence of drug-transporter polymorphisms in epilepsy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 505-512	5.5	13
50	Reconstruction and Analysis of Gene Networks of Human Neurotransmitter Systems Reveal Genes with Contentious Manifestation for Anxiety, Depression, and Intellectual Disabilities. <i>Genes</i> , 2019 , 10,	4.2	3
49	Pharmacogenetics and the treatment of epilepsy: what do we know?. <i>Pharmacogenomics</i> , 2019 , 20, 10	1932.1610	1 4
48	Polymorphisms and Drug-Resistant Epilepsy in a Tunisian Population. <i>Disease Markers</i> , 2019 , 2019, 134	436520	12

The Natural History of Epilepsy. 2020, 1-13 47 Challenges in Identifying Medication-Resistant Epilepsy. 2020, 14-19 46 International League Against Epilepsyll Definition of Medication-Resistant Epilepsy. 2020, 20-26 45 The Economic Impact of Medication-Resistant Epilepsy. 2020, 27-33 44 Social Consequences of Medication-Resistant Epilepsy. 2020, 34-38 43 Mortality and Morbidity of Medication-Resistant Epilepsy. 2020, 39-50 42 Models for Medication-Resistant Epilepsy. 2020, 51-61 41 Neurobiology of Medication-Resistant Epilepsy. 2020, 62-68 40 Genetic Causes of Medication-Resistant Epilepsy. 2020, 69-78 39 38 Malformations of Cortical Development as Causes of Medication-Resistant Epilepsy. 2020, 79-86 Hippocampal Sclerosis as a Cause of Medication-Resistant Epilepsy. 2020, 87-99 37 Autoimmune Causes of Medication-Resistant Epilepsy. 2020, 100-117 36 Medication-Resistant Epilepsy Syndromes in Children. 2020, 118-157 35 Medication-Resistant Epilepsy in Adults. 2020, 158-170 34 Approach to the Treatment of Medication-Resistant Epilepsy. 2020, 171-178 33 Pharmacotherapy for Medication-Resistant Epilepsy. **2020**, 179-186 32 Reproductive Health for Women with Medication-Resistant Epilepsy. 2020, 187-197 31 Resective Surgery for Medication-Resistant Epilepsy. 2020, 198-209 30

29	Ablative Surgery for Medication-Resistant Epilepsy. 2020 , 210-218		
28	Stimulation Treatment for Medication-Resistant Epilepsy. 2020 , 219-240		
27	Diet Therapy for Medication-Resistant Epilepsy. 2020 , 241-247		
26	Botanical Treatments for Medication-Resistant Epilepsy. 2020 , 248-255		
25	Psychiatric Comorbidities in Medication-Resistant Epilepsy. 2020 , 256-268		
24	ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 369-396	5.5	11
23	The association between MDR1 C3435T genetic polymorphism and the risk of multidrug-resistant epilepsy in Egyptian children. <i>Egyptian Journal of Medical Human Genetics</i> , 2021 , 22,	2	1
22	Predictive association of C3435T genetic polymorphism with the efficacy or safety of lopinavir and ritonavir in COVID-19 patients. <i>Pharmacogenomics</i> , 2021 , 22, 375-381	2.6	1
21	Disease-Induced Modulation of Drug Transporters at the Blood-Brain Barrier Level. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
20	The roles of variants in human multidrug resistance (MDR1) gene and their haplotypes on antiepileptic drugs response: a meta-analysis of 57 studies. <i>PLoS ONE</i> , 2015 , 10, e0122043	3.7	15
19	Correlation between ABCB1 gene polymorphisms, antiepileptic drug concentrations and treatment response. <i>Romanian Journal of Laboratory Medicine</i> , 2018 , 26, 479-487	0.3	5
18	Is the MDR1 C3435T polymorphism responsible for oral mucositis in children with acute lymphoblastic leukemia?. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012 , 13, 5251-5	1.7	15
17	Determining Pharmacological Intractability. Neurological Disease and Therapy, 2005, 3-19		
16	Efflux Transporters in the Brain. 2007 , 461-483		
15	Pharmacogenomics Applications in Epilepsy Chantal Depondt. <i>Methods in Pharmacology and Toxicology</i> , 2008 , 299-316	1.1	
14	Defining the Role of Anti-epileptic Pharmacogenetics in Psychiatric Drug Therapy. <i>Psychiatric Annals</i> , 2008 , 38,	0.5	
13	The Promise of Individualized Therapy. 1		
12	Pharmacogenetics of AED Development. 2010 , 159-172		

2

Genes Involved in Pharmacoresistant Epilepsy. 2013, 11-25 11 1 Genomics and Drug Transporters and Application in Drug Discovery, Delivery, and Development. 10 2018, 133-175 Index. 2020, 269-274 9 Medication-Resistant Epilepsy: Diagnosis and Treatment. 2020, 8 Pharmacogenetics of Drug-Resistant Epilepsy (Review of Literature). International Journal of 6.3 3 7 Molecular Sciences, 2021, 22, Associations between the C3435T polymorphism of the ABCB1 gene and drug resistance in 6 14 epilepsy: a meta-analysis. International Journal of Clinical and Experimental Medicine, 2014, 7, 3924-32 Polymorphism in drug transporter gene ABCB1 is associated with drug resistance in Pakistani 5 3 Ο epilepsy patients. Epilepsy Research, 2021, 178, 106814 Incidence and prevalence of major epilepsy-associated brain lesions.. Epilepsy and Behavior Reports, 1.3 **2022**, 18, 100527 The ABCB1, ABCC2 and RALBP1 polymorphisms are associated with carbamazepine response in 1.5 epileptic patient: a systematic review.. Acta Neurologica Belgica, 2022, 1

Association between ATP binding cassette gene member 1 polymorphism and glucocorticoid

Pharmacogenetic Study of the Impact of ABCB1 Single Nucleotide Polymorphisms on the Response

response in children with immune thrombocytopenia. 2022, 101, e29894

to Cyclosporine in Psoriasis Patients. 2022, 14, 2441